Research and development of healthcare insurance and 14 types of early cancer detection testing systems
First written in FY2019. 8 of 14 entries say "Restated". Latest entry: 2026-05-12.
No other company in this theme has enough history to compare yet.
- 2026-05-12AdvancedRevisions to earnings forecasts
「In the Medical business, we are focusing on 3 initiatives: domestic deployment of the communication app for healthcare professionals, Join (Join), overseas deployment, and Join Mobile Clinic, which combines portable medical equipment with Join, while also reducing fixed costs.」
The priority measures in the Healthcare and Medical business have been made specific: domestic and overseas expansion of Join, Join Mobile Clinic and fixed-cost reductions. - FY2026-H1AdvancedAnnual report
「In the healthcare business, revenue from data utilisation increased year on year, and the data health business also remained firm. In the medical business, we are focusing on three initiatives: domestic and overseas expansion of the medical-professional communication app "Join (Join)," and Join Mobile Clinic, which combines portable medical devices with Join. We are also reducing fixed costs.」
The healthcare and medical businesses identified specific priority areas: data utilisation and data health, domestic and overseas expansion of Join, Join Mobile Clinic, and fixed-cost reductions. - FY2025-H1AdvancedAnnual report
「The healthcare business reported lower revenue year on year, mainly because the year was not one in which a data health plan was formulated. Regarding data utilisation, the pipeline is progressing steadily toward the demand season in the second half. In the medical business, the number of facilities adopting the medical-professional communication app "Join (Join)" and other metrics continued to increase. Discussions are also under way on projects using Join Mobile Care, which combines portable medical devices with Join, with a view to contributing during the current fiscal year.」
Specific progress in the health big data and medical DX initiatives was described, including building the data-utilisation pipeline, increasing the number of facilities adopting Join and considering projects using Join Mobile Care. - FY2024AdvancedAnnual report
「In the healthcare and medical businesses, we will focus on health big data and medical DX (digital transformation), while building and promoting high-quality services and pursuing further growth and improved profitability.」
The description has progressed from existing healthcare services and upfront investment to explicitly focusing on health big data and medical DX, building and promoting services, and improving profitability. - FY2022ReframedAnnual report
「In the healthcare business, in addition to providing services and products that promote better health and behavioural change, we will accelerate initiatives including the health big data strategy and the development of industrial applications aimed at addressing social issues.」
The focus has shifted from descriptions of upfront investment in healthcare-type insurance and testing for 14 types of cancer to addressing social issues, including health-promotion services and industrial applications of health big data. - FY2022-Q3RestatedAnnual report
「The healthcare services business, including "kencom (Kencom)," remained firm and the Company continued to make upfront investment for the future. The segment nevertheless reported a profit in the third quarter of the fiscal year.」
The policy of continuing upfront investment for the future has been reaffirmed while existing healthcare services remain firm. - FY2022-Q2RestatedAnnual report
「Use of existing healthcare services, including "MYCODE (Mycode)" and "kencom (Kencom)," remained firm, while upfront investment was made for the future.」
The policy of making upfront investment for the future remains in place while use of existing healthcare services remains firm. - FY2022-Q1RestatedAnnual report
「Use of existing healthcare services, including "MYCODE (Mycode)" and "kencom (Kencom)," remained firm, while upfront investment was made for the future.」
The policy of making upfront investment for the future remains in place while use of existing healthcare services remains firm. - FY2021-Q3RestatedAnnual report
「Existing healthcare services and related businesses, including "MYCODE (Mycode)," "kencom (Kencom)" and "歩いておトク," remained firm, while upfront investment was made primarily in R&D.」
Existing healthcare services remained firm, while upfront investment, primarily in R&D, continued. - FY2021-Q2RestatedAnnual report
「Existing healthcare services and related businesses, including "MYCODE (Mycode)," "kencom (Kencom)" and "歩いておトク," remained firm, while upfront investment was made primarily in R&D.」
Existing healthcare services remained firm, while upfront investment, primarily in R&D, continued. - FY2020-Q3RestatedAnnual report
「Use of existing healthcare services, including "MYCODE (Mycode)," "kencom (Kencom)" and "歩いておトク," remained firm, while upfront investment was made primarily in R&D.」
Use of existing healthcare services remained firm, while upfront investment, primarily in R&D, continued. - FY2020-Q2RestatedAnnual report
「In R&D, we continued to make upfront investments, including the R&D by Preferred Networks, Inc. and our subsidiary PFDeNA of a testing system that uses deep-learning technology to detect 14 types of cancer at an early stage from a small blood sample.」
Upfront investment in a testing system using deep learning for the early detection of 14 types of cancer and other initiatives remains ongoing. - FY2020-Q1RestatedAnnual report
「In R&D, we continued to make upfront investments, including the R&D by Preferred Networks, Inc. and our subsidiary PFDeNA of a testing system that uses deep-learning technology to detect 14 types of cancer at an early stage from a small blood sample.」
Upfront investment in a testing system using deep learning for the early detection of 14 types of cancer and other initiatives by Preferred Networks and PFDeNA remains ongoing. - FY2019First statedAnnual report
「At the same time, we made upfront investments aimed at future business development, including initiatives to realise healthcare-type insurance and the R&D by Preferred Networks, Inc. and our subsidiary PFDeNA of a testing system that uses deep-learning technology to detect 14 types of cancer at an early stage from a small blood sample.」
Upfront investment is being made in realising healthcare-type insurance and developing a testing system that uses deep learning to detect 14 types of cancer at an early stage from a small blood sample.